Although reduced intensity conditioning (RIC) before allografting is associated with low treatment-related morbidity and mortality, graft-versus-host disease (GVHD) remains a significant complication of hematopoietic stem cell transplantation (HSCT). T cell depletion (TCD) has been successfully used in conventional allotransplantation to reduce the incidence of GVHD, but was associated with an increased rate of engraftment failure. In a small cohort of six patients at high risk of developing GVHD we have determined whether sustained engraftment could be achieved using reduced intensity conditioning and T cell depletion in combination. All patients engrafted and 5/6 developed high levels (ie у95%) of donor chimerism, even though mismatched related or matched unrelated donors were used. Only one patient developed acute GVHD, as he received donor lymphocyte infusions (DLI) for relapse. In summary, TCD might be a useful prophylactic tool in RIC allogeneic HSCT. Although TCD after RIC might be associated with high relapse rate, as 5/6 patients are not in remission, this combined strategy might be appropriate for patients with less aggressive malignant or non-malignant diseases in which high transplant-related morbidity and mortality is not acceptable.
(DLI), 1 there is growing interest in using HSCT as adoptive immunotherapy in other malignant diseases such as renal cell cancer 2 and even in non-malignant disorders such as chronic granulomatous disease or osteogenesis imperfecta. 3, 4 Transplant-related mortality associated with standard myeloablative transplantation regimens has been a major obstacle to the more widespread use of allogeneic HSCT. 5, 6 Based on animal studies, various groups 7, 8 have recently developed different reduced intensity conditioning (RIC) regimens to minimize transplant-related toxicity. The first human clinical trials have shown that mixed-hematopoietic chimerism can be achieved using these non-myeloablative regimens. 9, 10 Although such regimens appeared to be remarkably well tolerated in the early phase after transplantation, the incidence and severity of GVHD has remained one of the major determinants of morbidity and mortality similar to standard myeloablative protocols.
With conventional conditioning regimens, GVHD could be significantly reduced by T cell depletion (TCD) of the graft. 11 This ex vivo manipulation is however, associated with an increased risk of disease relapse 12 as well as of graft failure, which is believed to be caused by host lymphocytemediated rejection. 13 In RIC regimens, more intense postgrafting immunosuppression is used to control host immunity in order to allow engraftment. We have therefore proposed, that TCD might be a feasible approach in RIC transplants to reduce the incidence of GVHD. In the present study we have performed ex vivo TCD in combination with RIC in a cohort of patients at extremely high risk of developing acute GVHD.
We have shown, that complete chimerism could be achieved using this combined strategy, which is associated with very low transplant-related morbidity.
Materials and methods

Patients
Six patients in whom myeloablative conditioning was contraindicated, were included in this retrospective analysis. Patients received T cell-depleted grafts from either matched or mismatched family donors or from matched unrelated donors (UPN 6 and 8 received single antigen B and DR mismatched transplants, respectively.). All patients with multiple myeloma had chemosensitive relapse after one (n ϭ 3) or two (n ϭ 2) autologous transplantations. The other patient was diagnosed with secondary AML 1 year after completion of BEACOPP treatment for Hodgkin's disease and developed CNS relapse while AML treatment had to be withheld due to extensive pulmonary fungal disease. At time of transplantation this patient showed Ͻ5% blasts in the bone marrow and no evidence of meningeosis. The characteristics of patients and donors are described in Table 1 .
Preparative regimen
All patients received fludarabine 30 mg/m 2 from day Ϫ3 to Ϫ1 and 2 Gy TBI on day 0 for conditioning followed by intensive post-transplant immunosuppression using mycophenolate 2ϫ 15mg/kg p.o. twice a day from day 0 to ϩ28 and cyclosporine A 2ϫ 3mg/kg i.v. from day Ϫ1 to day ϩ35 and then slowly tapered until day 100. Dosing of CsA was adjusted according to CsA levels aimed at 400 ng/ml until day ϩ35.
Grafts
Ex vivo T cell depletion of the G-CSF mobilized hematopoietic progenitors was performed using a CD34 selection column (Miltenyi, Bergisch Gladbach, Germany). Results of graft processing are described in Table 2 . In order to reduce the risk of non-engraftment, T cells were added to bring the total number of infused T cells to 1 ϫ 10 5 /kg CD3 ϩ cells in five patients, whereas in one graft the CD3 ϩ cell number was 3 ϫ 10 5 /kg after CD34 enrichment and no further T cells were added.
Definition of response
For patients with multiple myeloma, complete response (CR) was defined by 5% or fewer plasmacytes of normal 
Small tandem repeats amplification and analysis
PCR of bone marrow or peripheral blood samples at days ϩ28, ϩ56 and ϩ100 was performed using the AmpFISTR Profiler PCR amplification kit (Applied Biosystems, Weiterstadt, Germany) as recommended by the manufacturer. Separation and detection of the amplified PCR products were performed on an ABI 310 automated sequencer (Applied Biosystems). The analysis of the results was performed using the Genescan 2.1 software (Applied Biosystems).
Results
Engraftment
Donor cells engrafted in all patients as shown in Table 2 .
In one patient with progressive multiple myeloma donor chimerism in the bone marrow declined, but this correlated with disease progression associated with Ͼ90% bone marrow infiltration. Conditioning therapy was very well tolerated, median time of ANC Ͻ0.5 ϫ 10 9 /l was 2 days and no platelet transfusions were required in any of the six patients, since platelet counts never dropped below 20 ϫ 10 9 /l. DLI DLI was given to three patients due to disease progression between days 80 and 100. Median cell dose was 1 ϫ 10 6 
CD3
ϩ cells per kg. Two patients did not respond to DLI and never developed GVHD. Both died due to progressive disease. One patient developed steroid-refractory grade IV GVHD of the liver which responded slowly to treatment with Mycophenolate. Two of three patients had Ͼ95% donor chimerism before DLI. In one patient (UPN 14), DLI could not prevent loss of donor chimerism due to medullary relapse.
GVHD
With a short follow-up of 225 days, 5/6 patients did not develop any signs of aGVHD. One patient transplanted from a sibling with a DR mismatch developed grade IV GVHD of the liver after DLI as mentioned above. No chronic GVHD has been diagnosed in these patients to date.
Infectious complications
Three of six patients showed CMV reactivation documented by PCR and pp65-antigen. In all patients treatment with ganciclovir resulted in clearance of virus DNA and no symptomatic CMV disease developed. One patient with progressive myeloma developed fungal pneumonia and died.
Response
Two of six patients died due to progressive disease. One of these two patients died due to tumor cachexia. This patient had extensive bone marrow involvement and consecutively lost donor chimerism. The second patient died from pneumonia as the myeloma progressed.
Three of six patients are in PR, while one patient is in CR.
Bone Marrow Transplantation
Discussion
Reduction of morbidity and mortality associated with the recently developed reduced intensity conditioning regimens has facilitated the use of allogeneic hematopoietic stem cell transplantation for solid tumors and non-malignant disorders. [2] [3] [4] While early mortality rate has decreased, GVHD has remained a major problem. 10, 14 T cell depletion of the graft, which in conventional, myeloablative transplantations was associated with increased risk for infectious complications, 15, 16 graft failure 13 and relapse, 12 could be a promising approach to reduce the incidence of GVHD. We have shown that TCD can be used safely after reduced intensity conditioning.
In our study all six patients have engrafted and 5/6 developed high levels (ie у95%) of donor chimerism. One patient showed disease progression with extensive bone marrow infiltration and subsequently lost the graft. This confirms recently published data by Craddock et al, 17 which show that TCD after various fludarabine-based reduced intensity regimens did result in sustained engraftment. While the vast majority of patients in the Craddock study were transplanted from HLA-identical sibling donors, matched unrelated donors and mismatched related donors were included in our cohort. The use of such donors is usually associated with higher risks of engraftment failure. In our series the addition of a defined number of CD3 positive cells might have resulted in sustained engraftment.
Various non-myeloablative conditioning regimens in a considerable range of intensity have been used by different groups. 9, 10, 14, 18 The conditioning regimen in the present study is among the less toxic regimens, as recently shown by Flowers et al. 19 In our series, only 50% of patients developed aplasia in contrast to 100% in the Craddock study. In addition, the median duration of days with ANC Ͻ0.5 ϫ 10 9 /l compares favorably to other published series.
9,14,18 Our observation suggests, that engraftment of TCD allografts could be achieved without undue toxicity after RIC even across HLA barriers and in the unrelated setting. Due to the short follow-up of 225 days in our study, no final conclusion can be drawn with respect to incidence of GVHD or the rate of infectious complications.
A major concern associated with TCD in myeloablative transplants was the high relapse rate. 12 This might be especially true for non-myeloablative approaches lacking the disease controlling effects of high-dose chemotherapy. Indeed, in our study, 5/6 patients are not in CR after transplantation, but with non-myeloablative transplants the developement of the GVL effect might occur late and it is not uncommon that a disease progression is noted early after transplant.
In conclusion, we have demonstrated that the combination of RIC and TCD could result in sustained engraftment, even in the unrelated and mismatch-related setting. Recent reports described potential use of allogeneic hematopoietic stem cell transplantation in non-malignant diseases such as chronic granulomatous disease and osteogenesis imperfecta. While the risk of disease progression and relapse in aggressive hematologic disorders needs to be further evaluated, our approach could be promising for non-malignant diseases and for situations where the relatively high transplant-related mortality and morbidity rates, usually associated with allogeneic stem cell transplantation, are not acceptable.
